Amneal Pharmaceuticals, Inc. (AMRX) reported a profit for its second quarter that Increased from last year and beat the Street estimates.
The company's earnings came in at $22.417 million, or $0.07 per share. This compares with $5.994 million, or $0.02 per share, last year.
Excluding items, Amneal Pharmaceuticals, Inc. reported adjusted earnings of $79.630 million or $0.25 per share for the period.
Analysts on average had expected the company to earn $0.17 per share. Analysts' estimates typically exclude special items.
The company's revenue for the period rose 3.2% to $724.508 million from $701.780 million last year.
Amneal Pharmaceuticals, Inc. earnings at a glance (GAAP) :
-Earnings: $22.417 Mln. vs. $5.994 Mln. last year.-EPS: $0.07 vs. $0.02 last year.-Revenue: $724.508 Mln vs. $701.780 Mln last year.
The company’s revenue was supported by Specialty revenue, which increased 23% driven by key branded products, including CREXONT, RYTARY, and UNITHROID. Revenue from Affordable Medicines also increased 1% driven by strong performance of the company’s complex product portfolio and new product launches.
Thus, the company’s increased second-quarter net income reflects improved revenue.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.